Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | SLRN | Series A Redeemable Convertible Preferred Stock | May 4, 2023 | Class A Common Stock | 4.06M | See footnote | F1, F2, F3 | |||||||
holding | SLRN | Series B Redeemable Convertible Preferred Stock | May 4, 2023 | Class A Common Stock | 2.45M | See footnote | F1, F2, F3 | |||||||
holding | SLRN | Series C Redeemable Convertible Preferred Stock | May 4, 2023 | Class A Common Stock | 2.04M | See footnote | F1, F2, F3 |
Id | Content |
---|---|
F1 | Each share of preferred stock is convertible into one share of Class A Common Stock or, subject to and in accordance with certain provisions set forth in the Issuer's certificate of incorporation, Class B Common Stock, and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock will automatically convert into shares of Common Stock. |
F2 | Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the IPO. |
F3 | Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. |
Exhibit 24 - Power of Attorney